GeneHealth - Your precision medicine

Iritis

Disease Details

Family Health Simplified

Buy Membership

Description: Iritis is the inflammation of the iris, the colored part of the eye, often causing redness, pain, and blurred vision.
Type: Iritis, also known as anterior uveitis, is an inflammatory condition affecting the iris of the eye. It is not typically considered a genetic disease with a specific pattern of genetic transmission. However, it can be associated with certain autoimmune diseases and genetic markers, such as HLA-B27. In such cases, there may be a genetic predisposition that increases the risk of developing iritis, but it is not inherited in a simple Mendelian fashion.
Signs And Symptoms: The disease course, anatomy, and laterality can vary widely and are important to consider in diagnosis and treatment. Cases may be acute (sudden onset with < 3 month duration) and monophonic, acute and recurrent, or chronic. The signs and symptoms of uveitis may include the following:
Prognosis: The prognosis is generally good for those who receive prompt diagnosis and treatment, but serious complication including cataracts, uveitic glaucoma, band keratopathy, macular edema and permanent vision loss may result if left untreated. The type of uveitis, as well as its severity, duration, and responsiveness to treatment or any associated illnesses, all factor into the outlook.
Onset: Iritis, also known as anterior uveitis, typically has a sudden onset. Symptoms often develop quickly over a few hours to days. They commonly include eye pain, redness, blurred vision, photophobia (sensitivity to light), and sometimes a small or irregularly shaped pupil. Early diagnosis and treatment are crucial to prevent complications and preserve vision.
Prevalence: Iritis, also known as anterior uveitis, is a relatively uncommon condition. Its prevalence varies by population, but it is estimated to occur at a rate of approximately 12 to 50 cases per 100,000 people annually. Different geographic regions and populations may exhibit varying prevalence rates due to genetic and environmental factors.
Epidemiology: Uveitis affects approximately 1 in 4500 people and is most common between the ages 20 to 60 with men and women affected equally. In western countries, anterior uveitis accounts for between 50% and 90% of uveitis cases. In Asian countries the proportion is between 28% and 50%. Uveitis is estimated to be responsible for approximately 10%-20% of the blindness in the United States.For non-infectious uveitis, women are more likely (57%) to be affected than men, possibly due to their higher prevalence of related autoimmune diseases. Vitamin D deficiency and smoking are risk factors for non-infectious uveitis.
Intractability: Iritis, also known as anterior uveitis, is not typically considered an intractable condition. It can often be managed effectively with appropriate medical treatment, such as corticosteroid eye drops and medications to dilate the pupil and reduce pain. However, if left untreated or if it is associated with an underlying systemic disease, it can lead to recurrent episodes and complications, which may require more extensive treatment. Managing underlying conditions and regular monitoring by an eye specialist can help prevent complications and recurrent episodes.
Disease Severity: Iritis, also known as anterior uveitis, refers to inflammation of the iris, the colored part of the eye. The disease severity can vary:

1. **Mild**: Symptoms may be subtle and include light sensitivity, mild eye pain, and slight redness.
2. **Moderate**: Noticeable redness, moderate eye pain, tearing, blurred vision, light sensitivity, and decreased visual acuity.
3. **Severe**: Intense eye pain, severe redness, significant tearing, pronounced light sensitivity, and substantial loss of vision. Complications such as glaucoma, cataracts, or macular edema can occur if untreated.

Iritis requires prompt medical attention to prevent complications. Treatment generally involves corticosteroid eye drops to reduce inflammation and dilating drops to relieve pain and prevent iris adhesions.
Healthcare Professionals: Disease Ontology ID - DOID:1406
Pathophysiology: Iritis, also known as anterior uveitis, is the inflammation of the iris, the colored part of the eye.

Pathophysiology:
1. **Immune Response:** The inflammation in iritis is often due to an autoimmune response, where the body's immune system attacks the iris, leading to inflammation.
2. **Infection:** It can also result from infections caused by viruses, bacteria, fungi, or parasites.
3. **Trauma:** Physical injury to the eye can trigger inflammatory processes.
4. **Associated Conditions:** Iritis is sometimes associated with systemic conditions like ankylosing spondylitis, rheumatoid arthritis, and inflammatory bowel disease.
5. **Cytokines and Cells:** The inflammation involves the release of cytokines and the infiltration of immune cells, such as T-cells, which aggravate and sustain the inflammatory process.

The exact mechanisms can vary based on the underlying cause, but the core process involves immune system mediation that leads to swelling, redness, pain, and potentially impaired vision if left untreated.
Carrier Status: Iritis, also known as anterior uveitis, is inflammation of the iris of the eye. It is not typically associated with a carrier status, as it is not a genetic disorder. Instead, iritis can result from infections, autoimmune conditions, or trauma.
Mechanism: Iritis is inflammation of the iris, the colored part of the eye. The mechanism involves an immune response that leads to inflammation. This can be caused by infections, autoimmune diseases, trauma, or other underlying conditions.

On a molecular level, the inflammation associated with iritis involves the activation of the immune system. Pro-inflammatory cytokines such as interleukins (e.g., IL-6, IL-8) and tumor necrosis factor-alpha (TNF-α) play a pivotal role in recruiting immune cells to the iris and surrounding tissues. These cytokines increase vascular permeability, allowing immune cells like macrophages and T-cells to infiltrate the area and contribute to the inflammatory response. Additionally, molecular pathways such as the NF-κB pathway are activated, further promoting the expression of inflammatory mediators. This complex interplay of immune responses leads to the clinical symptoms observed in iritis, such as redness, pain, and photophobia.
Treatment: Uveitis is typically treated with glucocorticoid steroids, either as topical eye drops (prednisolone acetate) or as oral therapy. Prior to the administration of corticosteroids, corneal ulcers must be ruled out. This is typically done using a fluorescence dye test. In addition to corticosteroids, topical cycloplegics, such as atropine or homatropine, may be used. Successful treatment of active uveitis increases T-regulatory cells in the eye, which likely contributes to disease regression.
In severe cases an injection of posterior subtenon triamcinolone acetate may also be given to reduce the swelling of the eye.
Intravitrial injection of steroid has proven to be a newer useful way to control inflammation for longer without the need for daily eyedrops. Dexamethasone and fluocinolone acetonide are two more commonly used options for noninfectious uveitis.Non-biologic, steroid sparing therapies for noninfectious uveitis in adults are now more available. These include the disease-modifying antirheumatic drugs (DMARDs) methotrexate, mycophenolate, cyclosporine, azathioprine, and tacrolimus. In comparing various studies, methotrexate is more efficacious than mycophenolate in inflammatory control for most forms of panuveitis. Methotrexate also had little to no differences in safety outcomes compared to mycophenolate.Antimetabolite medications, such as methotrexate are often used for recalcitrant or more aggressive cases of uveitis. Experimental treatments with Infliximab or other anti-TNF infusions may prove helpful.
The anti-diabetic drug metformin is reported to inhibit the process that causes the inflammation in uveitis.In the case of herpetic uveitis, anti-viral medications, such as valaciclovir or aciclovir, may be administered to treat the causative viral infection.
Compassionate Use Treatment: For iritis, compassionate use treatment and off-label or experimental treatments are sometimes considered when standard therapies are ineffective or inappropriate.

1. **Compassionate Use Treatment:**
- **Adalimumab (Humira):** This biologic is occasionally used under compassionate use programs for severe, recalcitrant uveitis, which includes iritis.
- **Infliximab (Remicade):** Another biologic agent that might be considered in certain severe cases under compassionate use.

2. **Off-label or Experimental Treatments:**
- **Methotrexate:** Although primarily used for rheumatoid arthritis and certain cancers, methotrexate can be prescribed off-label to treat chronic or severe iritis.
- **Mycophenolate mofetil:** Commonly used as an immunosuppressant in organ transplantation, it is sometimes used off-label for uveitis management.
- **Rituximab:** An anti-CD20 monoclonal antibody primarily used for B-cell non-Hodgkin lymphoma and rheumatoid arthritis, which can be considered for severe autoimmune-related uveitis.
- **Tocilizumab:** An interleukin-6 receptor inhibitor used in rheumatoid arthritis, which might be trialed off-label for cases unresponsive to other treatments.

These treatments are generally considered only after a thorough evaluation and under the guidance of a specialist.
Lifestyle Recommendations: Lifestyle recommendations for managing iritis include:

1. **Follow your treatment plan**: Adhere strictly to medications prescribed, such as corticosteroid eye drops, to reduce inflammation and pain.

2. **Protect your eyes**: Wear sunglasses to reduce light sensitivity (photophobia) and avoid any potential irritants.

3. **Limit close-up work**: Activities like reading or screen time can strain your eyes. Take regular breaks to rest them.

4. **Avoid smoking and alcohol**: These can exacerbate inflammation and slow the healing process.

5. **Manage stress**: Stress management techniques such as yoga or meditation may help, as stress can impact immune function.

6. **Monitor for underlying conditions**: Since iritis can be associated with autoimmune diseases, regular check-ups with your healthcare provider to monitor overall health are crucial.

7. **Diet and hydration**: Maintain a balanced diet rich in anti-inflammatory foods (such as fruits, vegetables, fatty fish) and stay hydrated to support overall eye health.
Medication: For iritis, a common treatment involves corticosteroid eye drops to reduce inflammation. Additionally, dilating eye drops may be prescribed to prevent muscle spasms in the iris and reduce pain. In some cases, oral steroids or other immunosuppressive medications are necessary. It's crucial to follow the treatment plan as prescribed by a healthcare professional.
Repurposable Drugs: Iritis, an inflammation of the iris, may see symptomatic relief with certain repurposable drugs. These can include:

1. **Corticosteroids (Topical and Oral)**: Prednisolone, Dexamethasone
2. **Cycloplegic Agents**: Atropine, Cyclopentolate
3. **Nonsteroidal Anti-inflammatory Drugs (NSAIDs)**: Diclofenac, Ketorolac

Proper diagnosis and treatment by an ophthalmologist are essential.
Metabolites: In iritis, also known as anterior uveitis, specific metabolites that may be involved include inflammatory cytokines and immune mediators like TNF-alpha, interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). Changes in these metabolites may indicate inflammation and immune response in the eye. Elevated levels of these cytokines and other immune-related metabolites can often be detected in the aqueous humor of patients with iritis. Nanotechnology (nan) is being explored to develop targeted drug delivery systems to manage and treat inflammation in iritis more effectively. Nanoparticles can potentially deliver anti-inflammatory drugs directly to the affected tissues, improving therapeutic outcomes and reducing side effects.
Nutraceuticals: For iritis, there isn't strong evidence to support the use of specific nutraceuticals (dietary supplements with medicinal benefits) as primary treatment. The condition is typically managed with corticosteroids and dilating eye drops to reduce inflammation and pain. However, some general anti-inflammatory supplements such as omega-3 fatty acids, curcumin (found in turmeric), and vitamin D might help support overall eye health. It's important to consult with a healthcare professional before starting any new supplements.
Peptides: Peptide therapy for iritis involves using specific peptides that may modulate the immune response to reduce inflammation in the eye. Research into these therapies is ongoing, aiming to discover effective treatments with fewer side effects compared to conventional medications like corticosteroids. Current available treatments for iritis primarily include corticosteroids, cycloplegic agents, and immunosuppressive drugs.

Nanotechnology in iritis treatment explores the use of nanoparticles to deliver drugs directly to the affected eye tissue, enhancing the efficacy and reducing systemic side effects. Nanopharmaceuticals can provide controlled and sustained release of therapeutic agents, potentially improving patient outcomes and compliance. Research is still in various stages, but this area holds promising potential for the future management of iritis.